STOCKHOLM, SWEDEN / RankWire.AI / – The 2026 Nobel Prize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their groundbreaking work that established the field of optogenetics. Announced on October 5 by the Nobel Assembly at Karolinska Institutet, the honor highlights their contributions to enabling scientists to precisely control specific nerve cells using light. Their discoveries have become fundamental in research on brain circuitry, behavior, memory, and neurological diseases, establishing themselves as some of neuroscience’s most vital experimental techniques.
Hegemann and Nagel’s research uncovered the mechanism behind channelrhodopsin in the green alga Chlamydomonas. They demonstrated that this protein creates a light-activated channel within the cell membrane, where blue light opens the channel and allows charged ions to pass through, thus inducing electrical activity in the cell. Their experiments proved that channelrhodopsin could be expressed in other cell types, making it possible to control those cells with light—a discovery that laid the groundwork for manipulating cellular activity through light flashes.
Deisseroth adapted this insight for neuroscience. In 2005, he demonstrated that channelrhodopsin could be used to make rat neurons respond to blue light, showing that electrical signals could be triggered in specific neurons with light stimulation. Subsequent research confirmed that this method worked in living animals, transforming optogenetics into a practical approach for investigating how particular brain circuits influence activity and behavior. Compared to earlier techniques, this method offers unprecedented precision and control.
Optogenetics’ ability to control light transforms brain research
Optogenetics integrates genetic techniques with light-sensitive proteins, enabling researchers to activate or silence specific groups of neurons. Scientists use this technology to explore how individual neural circuits contribute to behaviors such as movement, learning, emotion, and memory. The Nobel Committee emphasized that this approach has revolutionized in vivo brain studies by allowing scientists to link activity in targeted cells to observable behavioral changes, without indiscriminately stimulating entire tissue regions.
Today, optogenetics is employed in research into conditions like Parkinson’s disease, epilepsy, depression, addiction, and beyond. It is also being tested as a potential treatment for severe vision loss, aiming to restore light sensitivity in retinal cells. These medical applications are still in experimental stages and are not yet standard treatments. Nonetheless, the method’s primary current role remains in research, where it enables detailed analysis of complex biological systems. Its use has expanded beyond neuroscience into other fields of cell biology as well.
The three scientists awarded share the Nobel prize in medicine
Deisseroth is based at Stanford University and conducts research with the Howard Hughes Medical Institute in the US. Hegemann is affiliated with Humboldt University of Berlin, while Nagel is associated with the University of Würzburg in Germany. The laureates will divide 12 million Swedish kronor among themselves. Their work represents key stages in the evolution of modern optogenetics—from identifying light-sensitive proteins, to characterizing their functions, to applying them for precise neural control.
This award acknowledges a scientific journey that began with a simple organism and profoundly transformed neuroscience. Channelrhodopsin served as the molecular switch enabling exact light-based control. Deisseroth’s contribution helped incorporate this switch into nerve cells and living brains. Today, optogenetics is widely used across neuroscience and other biological sciences. The Nobel laureates will receive their medals and diplomas in Stockholm on December 10, coinciding with the anniversary of Alfred Nobel’s death, in keeping with longstanding Nobel traditions.